Graham Collins, MBBS, MA, MRCP, FRCPath, DPhil, is a Consultant Hematologist at Oxford University Hospitals NHS Foundation Trust in Oxford, UK. He is also the Clinical Lead at the Oncology Clinical Trials Office in Oxford, UK, and Chair of the National Cancer Research Institute (NCRI) UK Hodgkin study group.
Dr Collins received his MA in medical sciences from the University of Cambridge, Cambridge, UK, before receiving an MBBS in medicine from Queen Mary University of London, London, UK. After this he completed a DPhil in molecular pathology and specialist hematology training at the University of Oxford, Oxford, UK.
Dr Collins is a member of the lymphoma guidelines development group of the National Institute for Health and Care Excellence (NICE) and has co-authored the national guidelines for relapsed Hodgkin lymphoma. He is also a trustee of the national Lymphoma Association.
Speaking on immunotherapies for Hodgkin lymphoma
Dr Collins has a specific research interest in novel clinical trials that assess treatments for diffuse large B-cell lymphoma, Hodgkin lymphoma and T-cell lymphoma. In particular, Dr Collins studies lymphoproliferative disorders and immunotherapy drugs in early treatment settings and he has been the principal investigator on multiple clinical trials investigating immunotherapies for Hodgkin lymphoma.